Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lucid Diagnostics Inc (NQ: LUCD )

0.9868 -0.0232 (-2.30%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lucid Diagnostics Inc

< Previous 1 2 3 4 Next >
PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
From Lucid Diagnostics Inc.
Via Business Wire
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter. 
Via Benzinga
Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Provides Business Update and Third Quarter 2022 Financial Results
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
From Lucid Diagnostics Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio
From Lucid Diagnostics Inc.
Via Business Wire
Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements
From Lucid Diagnostics Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million. 
Via Benzinga
Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics to Hold a Business Update Conference Call on May 11, 2022
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans
From Lucid Diagnostics Inc.
Via Business Wire
How Is The Market Feeling About Lucid Diagnostics Inc. - Common Stock?
Lucid Diagnostics Inc. - Common Stock's (NASDAQ:LUCD) short percent of float has fallen 4.35% since its last report. The company recently reported that it has 378.70 thousand... 
Via Benzinga
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
From Lucid Diagnostics Inc.
Via Business Wire
10 Biggest Price Target Changes For Tuesday
BTIG cut the price target on NeoGenomics, Inc. (NASDAQ: NEO) from $35 to $28. NeoGenomics shares fell 29.2% to $12.60 in pre-market trading. 
Via Benzinga
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference
From Lucid Diagnostics Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV) shares moved upwards by 55.5% to $2.13 during Thursday's pre-market session. The market value of their outstanding... 
Via Benzinga
PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
From Lucid Diagnostics Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.